NAVB - Navidea Biopharmaceuticals, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
1.3839
-0.0461 (-3.22%)
At close: 3:51PM EDT
Stock chart is not supported by your current browser
Previous Close1.4300
Open1.4200
Bid1.3700 x 1300
Ask1.4500 x 800
Day's Range1.3770 - 1.4206
52 Week Range1.2100 - 7.4000
Volume13,349
Avg. Volume46,738
Market Cap13.891M
Beta (3Y Monthly)1.45
PE Ratio (TTM)N/A
EPS (TTM)-1.3110
Earnings DateMar 24, 2017 - Mar 27, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.25
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents3 days ago

    Edited Transcript of NAVB earnings conference call or presentation 8-May-19 9:00pm GMT

    Q1 2019 Navidea Biopharmaceuticals Inc Earnings Call

  • Associated Press14 days ago

    Navidea: 1Q Earnings Snapshot

    On a per-share basis, the Dublin, Ohio-based company said it had a loss of 24 cents. The biopharmaceutical posted revenue of $136,000 in the period. In the final minutes of trading on Wednesday, the company's ...

  • Business Wire14 days ago

    Navidea Biopharmaceuticals Reports First Quarter 2019 Financial Results

    Conference Call to be held Wednesday, May 8, 2019 at 5:00 pm ET

  • Business Wire21 days ago

    Navidea Biopharmaceuticals Schedules First Quarter 2019 Earnings Conference Call and Business Update

    Conference Call to be held Wednesday, May 8, 2019 at 5:00 p.m.

  • Business Wire26 days ago

    Navidea Biopharmaceuticals Announces Comparative Study to Evaluate the Potential Utility of Tilmanocept In Patients with Tuberculosis (“TB”)

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that Professor Mike Sathekge, MBChB, M. Med (Nuclear Medicine), PhD Professor and Head of the Department of Nuclear Medicine in the Faculty of Health Sciences at the University of Pretoria/Steve Biko Academic Hospital, plans to initiate a comparative study evaluating the use of Tilmanocept in patients with TB. A molecular probe such as 68Ga-labeled Tilmanocept targeting MR (CD206) expressed on macrophages, therefore, holds great promise not only in understanding the behavior of TB granulomas, but may serve as a vehicle for delivering therapeutic interventions in the future.

  • Business Wirelast month

    Navidea Biopharmaceuticals Announces Reverse Stock Split

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Board of Directors has approved a one-for-twenty reverse stock split of its issued and outstanding shares of common stock. The reverse split will be effective at 12:01 a.m. (EDT) on April 26, 2019, and shares of the Company’s common stock will begin trading on a split-adjusted basis when the NYSE American market opens on that date.

  • Business Wirelast month

    Navidea Biopharmaceuticals Receives FDA Feedback Regarding Rheumatoid Arthritis Clinical Trial Design and Provides Business Updates

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it received feedback from the U.S Food and Drug Administration (“FDA”) regarding the Company’s planned clinical studies that will evaluate joint disease in patients with Rheumatoid Arthritis (“RA”) and monitor patient response to therapy. The Company’s proposed RA studies were discussed with the FDA during an in-person meeting, and through follow-up collaborative efforts.

  • Business Wire2 months ago

    Navidea Biopharmaceuticals Data to be Presented at Society of Nuclear Medicine and Molecular Imaging Annual Meeting

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that Arash Kardan, M.D., will give an oral presentation on the results of the Company’s NAV3-21 clinical study at the Society of Nuclear Medicine and Molecular Imaging (“SNMMI”) Annual Meeting in June 2019. Images were acquired one hour and three hours post-injection of Tc99m tilmanocept. Results from the completed trial demonstrate that Tc99m tilmanocept is well-tolerated with no serious adverse events, adverse drug reactions, or drug-related adverse events observed.

  • Business Wire2 months ago

    Navidea Biopharmaceuticals Announces Stock Purchase Agreement; Other Business Updates

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced execution of a Stock Purchase Agreement (the “Purchase Agreement”) with an existing investor, John K. Scott, Jr. (the “Investor”), pursuant to which the Company will issue to the Investor in a private placement (the “Private Placement”) up to $3.0 million in shares (the “Securities”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”).

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of NAVB earnings conference call or presentation 7-Mar-19 10:00pm GMT

    Q4 2018 Navidea Biopharmaceuticals Inc Earnings Call

  • Business Wire2 months ago

    Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

    Conference Call to be held Thursday, March 7, 2019 at 5:00 pm ET

  • Business Wire3 months ago

    Navidea Biopharmaceuticals Schedules Fourth Quarter 2018 Earnings Conference Call and Business Update

    Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or “the Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call on Thursday, March 7th, 2019, at 5:00 pm ET to discuss its financial results for the fourth quarter of 2018 in conjunction with the filing of its annual report on Form 10-K. Jed Latkin, Chief Executive Officer, and Erika Gibson, Director, Finance and Administration, of Navidea will host the call and provide an update on recent developments and clinical progress. Management will be answering questions live immediately following the financial earnings portion of the conference call.

  • Business Wire4 months ago

    Navidea Biopharmaceuticals Announces Extension of NYSE American Listing

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the receipt of a notice from the NYSE American LLC (the “NYSE American”) on January 28, 2019 that the NYSE American has granted the Company an extension until March 31, 2019 to regain compliance with Section 1003(f)(v) of the NYSE American’s continued listing standards. Navidea previously disclosed that it received a notification from the NYSE American stating that Navidea was not in compliance with certain provisions of the NYSE American continued listing standards, including Section 1003(f)(v), which relates to the selling price per share of the Company’s securities.

  • Business Wire4 months ago

    Navidea Biopharmaceuticals Announces Decision by Ohio Supreme Court

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the Ohio Supreme Court has dismissed a Petition filed by Capital Royalty Partners II, L.P. and affiliated entities. On August 27, 2018, Capital Royalty Partners II, L.P. and several affiliated entities ("CRG") filed a Petition with the Ohio Supreme Court seeking a Writ of Prohibition against the Honorable Mark A. Serrott asserting that Judge Serrott's refusal to dismiss Navidea Biopharmaceuticals, Inc.'s pending Ohio litigation against CRG was improper and that Judge Serrott lacked jurisdiction over CRG with respect to the case issues.

  • Business Wire5 months ago

    Navidea Biopharmaceuticals Announces Patent Extension for Lymphoseek®

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on November 23, 2018 the U.S. Food and Drug Administration (“FDA”) released a letter to the U.S. Patent and Trademark Office (“USPTO”) indicating that the USPTO is allowed to extend the patent duration of U.S. patent 6,409,990 for an additional 5 years or until May 12, 2025. This patent claims Lymphoseek® (technetium (Tc 99m) tilmanocept) and has been exclusively licensed with varying geographical and medical indication coverages to Cardinal Health and Navidea. Allowance of this patent extension will permit Cardinal Health and Navidea to extend their exclusive rights to manufacture and commercialize Lymphoseek until the end of the extended patent term in 2025.

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of NAVB earnings conference call or presentation 7-Nov-18 9:30pm GMT

    Q3 2018 Navidea Biopharmaceuticals Inc Earnings Call

  • Business Wire6 months ago

    Navidea Biopharmaceuticals Appoints Adam Cutler to Board of Directors

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Adam Cutler to the Company’s board of directors, effective December 1, 2018. “We are pleased to welcome Mr. Cutler to Navidea’s board of directors,” said Mr. Jed A. Latkin, Chief Executive Officer of Navidea.

  • Business Wire6 months ago

    Navidea Biopharmaceuticals Appoints Dr. Michael Rosol as Chief Medical Officer

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Michael Rosol, PhD as Chief Medical Officer of Navidea, effective December 17, 2018. Dr. Rosol brings to this position over 10 years of experience in biomedical imaging and commercialization.

  • Business Wire6 months ago

    Navidea Biopharmaceuticals to Present at the 11th Annual LD Micro Event 2018

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Chief Executive Officer, Jed Latkin, will present a corporate overview of the Company at the 11th Annual LD Micro Event, being held December 4-6, 2018 in Bel-Air, California. The LD Micro Event is one of the largest and most influential independent micro-cap conferences. Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics.

  • Business Wire6 months ago

    Navidea Biopharmaceuticals Announces Presentation at the Radiological Society of North America (RSNA) 104th Scientific Assembly and Annual Meeting 2018

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that Dr. David Ralph, Director of Drug Development and IP Manager of Navidea, will be presenting at the RSNA 104th Scientific Assembly and Annual Meeting, which is taking place November 25-30, 2018 in Chicago, IL. The oral presentation will highlight an abstract evaluated and selected through a competitive, blind peer-review process.

  • Business Wire6 months ago

    Navidea Biopharmaceuticals Appoints Dr. Kathy Rouan to Board of Directors

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Kathy Rouan, PhD, to the Company’s board of directors, effective December 1, 2018. “We are excited for Dr. Rouan to join Navidea’s board of directors at an instrumental time in the Company’s development,” said Mr. Jed A. Latkin, Chief Executive Officer of Navidea.

  • GlobeNewswire6 months ago

    Recent Analysis Shows Aquantia, Ubiquiti Networks, Reliv' International, Permian Basin Royalty Trust, Patriot Transportation Holding, and Navidea Biopharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Associated Press6 months ago

    Navidea: 3Q Earnings Snapshot

    On a per-share basis, the Dublin, Ohio-based company said it had a loss of 2 cents. The biopharmaceutical posted revenue of $231,500 in the period. Its adjusted revenue was $231,000. In the final minutes ...

  • Business Wire6 months ago

    Navidea Biopharmaceuticals Reports Third Quarter 2018 Financial Results

    Conference Call to be held Wednesday, November 7th, 2018 at 4:30 pm ET

  • Business Wire7 months ago

    Navidea Biopharmaceuticals Schedules Third Quarter 2018 Earnings Conference Call and Business Update

    Conference call to take place November 7th, 2018, at 4:30 pm E.T.